We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+12.53%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$3.25B
AUM Growth
+$307M
Cap. Flow
+$95.8M
Cap. Flow %
2.95%
Top 10 Hldgs %
41.75%
Holding
101
New
19
Increased
28
Reduced
23
Closed
18

Top Buys

1
CI icon
Cigna
CI
+$68.6M
2
ALLK
Allakos
ALLK
+$59.9M
3
WMGI
Wright Medical Group Inc
WMGI
+$58.6M
4
FATE icon
Fate Therapeutics
FATE
+$43.8M
5
REPL icon
Replimune Group
REPL
+$38.4M

Top Sells

1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.7M
2
WCG
Wellcare Health Plans, Inc.
WCG
+$56.5M
3
LH icon
Labcorp
LH
+$51.8M
4
INSM icon
Insmed
INSM
+$48.1M
5
CNC icon
Centene
CNC
+$39.7M

Sector Composition

1 Healthcare 93.71%
2 Financials 1.28%
3 Energy 0.69%
4 Technology 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
51
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$19.7M 0.61%
165,614
+2,490
+2% +$289K
ELAN icon
52
Elanco Animal Health
ELAN
$13B
$18.3M 0.56%
+525,000
New +$18.5M
TCDA
53
DELISTED
Tricida, Inc. Common Stock
TCDA
$15.1M 0.47%
495,000
-5,000
-1% -$147K
CMRX
54
DELISTED
Chimerix, Inc.
CMRX
$14M 0.43%
3,591,050
+1,560
+0% +$6.64K
ODT
55
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$11.7M 0.36%
605,300
-5,300
-0.9% -$108K
SGRY icon
56
Surgery Partners
SGRY
$2.18B
$10.5M 0.32%
634,400
+13,100
+2% +$209K
NVTA
57
DELISTED
Invitae Corporation
NVTA
$8.79M 0.27%
525,375
-286,865
-35% -$3.26M
EIDX
58
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$8.66M 0.27%
867,700
+676,700
+354% +$11.1M
IIN
59
DELISTED
IntriCon Corporation
IIN
$7.03M 0.22%
+125,000
New +$7.32M
ONC
60
BeOne Medicines Ltd
ONC
$32.9B
$6.94M 0.21%
40,300
– –
STIM icon
61
Neuronetics
STIM
$124M
$5.8M 0.18%
180,999
-119,001
-40% -$3.62M
OVID icon
62
Ovid Therapeutics
OVID
$457M
$4.14M 0.13%
730,150
+608,200
+499% +$4.61M
ESTA icon
63
Establishment Labs
ESTA
$2.72B
$3.62M 0.11%
+150,000
New +$3.85M
JNCE
64
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.77M 0.09%
425,415
-789,178
-65% -$5.87M
ARVN icon
65
Arvinas
ARVN
$518M
$2.3M 0.07%
+136,300
New +$2.24M
ELGX
66
DELISTED
Endologix Inc
ELGX
$1.55M 0.05%
81,046
-351,593
-81% -$12.5M
VTAK icon
67
Catheter Precision
VTAK
$2.31M
– –
0
– –
RGEN icon
68
Repligen
RGEN
$8.38B
$1.11M 0.03%
+20,000
New +$1.03M
VKTX icon
69
Viking Therapeutics
VKTX
$4.22B
$523K 0.02%
+30,000
New +$357K
MYOK
70
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$467K 0.01%
7,170
– –
IHF icon
71
iShares US Healthcare Providers ETF
IHF
$1.19B
$417K 0.01%
10,435
– –
HRTX icon
72
Heron Therapeutics
HRTX
$90.1M
$343K 0.01%
+10,850
New +$404K
AMED
73
DELISTED
Amedisys
AMED
$341K 0.01%
2,725
– –
SAGE
74
DELISTED
Sage Therapeutics
SAGE
$307K 0.01%
2,170
– –
VCEL icon
75
Vericel Corp
VCEL
$2.44B
$283K 0.01%
20,000
-160,873
-89% -$1.89M
1 2
3
4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q3 2018 Portfolio in Review

As of Q3 2018, Redmile Group held 101 positions worth $3.25B, up 10% from $2.94B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group's Q3 2018 filing shows 19 new, 28 increased, 23 reduced and 18 closed positions. Its largest new stake was Cigna: 370,200 shares worth $77.1M. The largest sale was Alexion Pharmaceuticals, an estimated $60.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Energy.

  • Redmile Group's largest Q3 2018 buy was Cigna: 370,200 shares worth $77.1M.
  • Redmile Group added most to Fate Therapeutics in Q3 2018, an estimated $43.8M increase.
  • Redmile Group's biggest Q3 2018 reduction was Wellcare Health Plans, Inc., cutting an estimated $56.5M.
  • Redmile Group fully exited Alexion Pharmaceuticals in Q3 2018, selling an estimated $60.7M.
  • Redmile Group's ten largest holdings make up 42% of its $3.25B portfolio in Q3 2018.
  • Redmile Group opened 19 new positions and closed 18 in Q3 2018.
  • Redmile Group's portfolio value rose 10% quarter-over-quarter to $3.25B.

Based on Redmile Group's 13F filing for Q3 2018, filed 14 Nov 2018.